Olema Oncology

Olema Oncology is a clinical-stage biotech focused on transforming the treatment of endocrine-driven cancers, particularly metastatic ER+/HER2- breast cancer. Its core achievement is the development of palazestrant, an oral CERAN/SERD with a dual mechanism of action, now in two pivotal Phase 3 trials with top-line monotherapy data expected in fall 2026. The company's strategy leverages deep scientific expertise in nuclear receptors to address the critical unmet need of therapy resistance, aiming to establish palazestrant as a new standard of care. A second asset, OP-3136, a KAT6 inhibitor, represents a novel epigenetic approach currently in Phase 1.

Expertise in nuclear receptor biology and small molecule drug design, focused on developing complete estrogen receptor antagonists (CERAN) and degraders (SERD) to overcome therapy resistance, with extension into epigenetic targets like KAT6.